Denosumab
Description
Denosumab is a human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL). It was approved for the treatment of osteoporosis in postmenopausal women.
Product name | Denosumab Biosimilar |
Species | Homo sapiens |
Expression system | CHO-K1 |
Buffer | PBS, pH 7.4 |
Delivery condition | Dry ice (-80°C) |
Delivery Time | 1 week if in stock; 4 weeks if production needed |
Storage condition | Store at -80°C |
Brand | BioMetas |
Applications | ELISA, assay, in vivo |
Aliases/Synonyms | Xgeva, Prolia, AMG162 |
Reference | |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Type | hIgG2, κ |
Clonality |
Size | 1mg, 5mg, 10mg, 50mg, 100mg |
Brand | BioMetas |
Product type | Biosimilar |
Clonality | Monoclonal Antibody |
Expression system | CHO-K1 |
Applications | Elisa, assay, in vivo |
Contact Us for a Quote!
Data Gallery
Fig. 1.) 4-20% SDS-PAGE analysis
Recombinant protein was visualized by Coomassie Brilliant Blue R250 staining.
Fig. 2.) SEC-HPLC analysis
Column: Superdex 200 Increase 5/150 GL
Running buffer: 2xPBS, pH 7.4
